Yanagawa Bobby, Mazine Amine, Tam Derrick Y, Jüni Peter, Bhatt Deepak L, Spindel Stephen, Puskas John D, Verma Subodh, Friedrich Jan O
From the Division of Cardiac Surgery.
Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA USA.
Innovations (Phila). 2018 May/Jun;13(3):163-170. doi: 10.1097/IMI.0000000000000510.
Surgical management of aortic valve infective endocarditis (IE) with cryopreserved homograft has been associated with lower risk of recurrent IE, but there is equipoise with regard to the optimal prosthesis. This systematic review and meta-analysis were performed to compare outcomes between homograft and conventional prosthesis for aortic valve IE.
We searched MEDLINE database to September 2017 for studies comparing homograft versus conventional prosthesis. The main outcomes were all-cause mortality, recurrent IE, and reoperation.
There were 18 included comparative observational studies with 2232 patients (median follow up = 5 [interquartile range: 2-7] years, 30% prosthetic valve endocarditis); four studies were adjusted for baseline differences. There were no differences in perioperative mortality or stroke despite a greater proportion of staphylococcal endocarditis, abscess, and root replacements but less multivalve involvement in the homograft group. Long-term outcomes of all-cause mortality [incidence rate ratio (IRR) = 1.03, 95% confidence interval (CI) = 0.81-1.31, P = 0 .83, for unmatched, and IRR = 0.82, 95% CI = 0.36-1.84, P = 0.63, for matched studies], recurrent endocarditis (IRR = 1.01, 95% CI = 0.53-1.93, P = 0.96, for unmatched, and IRR = 1.04, 95% CI = 0.49-2.19, P = 0.92, for matched studies), and reoperation (IRR = 1.60, 95% CI = 0.80-3.21, P = 0.18, for unmatched, and IRR = 3.17, 95% CI = 0.52-19.44, P = 0.21, for matched studies) were not different comparing homograft versus conventional prosthesis. There was a significantly increased need for reoperation with homograft versus mechanical prosthetic valves, but this comparison was based on limited data.
Homografts and conventional prostheses offer similar survival and freedom from recurrent endocarditis and reoperation for aortic valve IE. Homografts may be associated with greater risk of reoperation compared with mechanical valves.
采用低温保存同种异体移植物进行主动脉瓣感染性心内膜炎(IE)的外科治疗与较低的IE复发风险相关,但关于最佳假体仍存在平衡。进行这项系统评价和荟萃分析以比较同种异体移植物和传统假体治疗主动脉瓣IE的疗效。
检索MEDLINE数据库至2017年9月,查找比较同种异体移植物与传统假体的研究。主要结局为全因死亡率、IE复发和再次手术。
纳入18项比较性观察性研究,共2232例患者(中位随访时间 = 5 [四分位间距:2 - 7]年,30%为人工瓣膜心内膜炎);4项研究对基线差异进行了校正。尽管同种异体移植物组葡萄球菌性心内膜炎、脓肿和根部置换的比例更高,但多瓣膜受累情况较少,但围手术期死亡率或卒中无差异。比较同种异体移植物与传统假体,全因死亡率[发病率比值(IRR) = 1.03,95%置信区间(CI) = 0.81 - 1.31,P = 0.83(未匹配),IRR = 0.82,95% CI = 0.36 - 1.84,P = 0.63(匹配研究)]、心内膜炎复发(IRR = 1.01,95% CI = 0.53 - 1.93,P = 0.96(未匹配),IRR = 1.04,95% CI = 0.49 - 2.19,P = 0.92(匹配研究))和再次手术(IRR = 1.60,95% CI = 0.80 - 3.21,P = 0.18(未匹配),IRR = 3.17,95% CI = 0.52 - 19.44,P = 0.21(匹配研究))无差异。与机械瓣膜相比,同种异体移植物再次手术的需求显著增加,但该比较基于有限的数据。
对于主动脉瓣IE,同种异体移植物和传统假体在生存率、免于心内膜炎复发和再次手术方面提供相似的效果。与机械瓣膜相比,同种异体移植物可能与更高的再次手术风险相关。